242:
two companies would continue to work together as per their agreed terms. The drug is still under its process of development even after going through several rounds of clinical trials and tests. The initial trials of the drug failed in traditional ways but still the hope of its prospects remained as claimed by the inventor Dr. Folkman. In 2005, EndoStar, a new variant of the drug
Endostatin was introduced by a group of Chinese scientists with the support of Luo Yongzhang, one of the investors of EntreMed. This variation was developed with the aim to carry out the clinical trials on the population of China. Experts have preferred to wait further to study the trials, effects and analyze the outcome before concluding anything decisively.
25:
229:
what was expected. The report also said that the two potential 'weak drugs' had the ability to reduce cancer growth considerably and will be manufactured by EntreMed. The associated research and potential of the drugs and its prospects was proclaimed by the
Harvard researcher Dr. Judah Folkman who was known for working to choke off the blood supply to tumor cells for over three decades.
241:
to carry out R&D about the development of the final drug depending on the base angiostain protein. Bristol-Myers Squibb announced its decision not to continue researching the drug next year. Though the CEO of EntreMed said that such an announcement was 'frustrating' and a 'non-event', he said the
250:
During June 2014 EntreMed was renamed to CASI pharmaceuticals through the voting process of the shareholders of the company. In the letter to the shareholder, the CEO at that time, Ken K. Ren said "The new name is in furtherance of the remaking of EntreMed and reflects our mission to combat cancer
228:
which was said to work interfering with the supply of blood required by the tumors. It was also said that the tumors are removed with such treatments. Though the report commented on the high expectations already invoked by previous research and prospective candidates its ultimate results were not
233:
stated in reference to the report that "Judah is going to cure cancer in two years". After the NYT story was published, the stock price of EntreMed went up to $ 83 from $ 12. During the latter half of that year several uncertainties regarding the effectiveness of the manufacture of the drug was
254:
In August 2019, CASI Pharmaceuticals obtained approval for selling
Evomela (an injection treatment for patients with multiple Myelom) to the population of China. This was the first product by the company to be sold to the open market despite it being founded in 1991.
49:
762:
219:
reported a story about a developing drug in the research stage claiming that the same would lead to "eradicate any type of cancer" and "with no obvious side effects". The treatment was supposed to be based on
396:
Sheinfeld, J., Bochner, B. H., Zelefsky, M. J., Rini, B. I., Scardino, P. T. (2015). Comprehensive
Textbook of Genitourinary Oncology. United States: Wolters Kluwer Health/Lippincott Williams & Wilkins.
329:
Plunkett's
Biotech & Genetics Industry Almanac 2006: The Only Complete Reference to the Business of Biotechnology and Genetic Engineering. (2005). United States: Plunkett Research.
309:
Adler, D. E. (2009). Snap
Judgment: When to Trust Your Instincts, When to Ignore Them, and How to Avoid Making Big Mistakes with Your Mone. (n.p.): Pearson Education.
830:
426:
835:
349:
Eaton, M. L., Kennedy, D. (2007). Innovation in
Medical Technology: Ethical Issues and Challenges. United States: Johns Hopkins University Press.
845:
825:
207:
in the year 1991 by Peter C. Farrell, Bart
Chernow and John Holaday. Holaday was the CEO of the company until 2002. He died in October 2019.
506:
795:
681:
647:
557:
339:
Abate, T. (2013). The
Biotech Investor: How to Profit from the Coming Boom in Biotechnology. United States: Henry Holt and Company.
840:
289:
Choudhary, M. I. (2011). Frontiers in Anti-Cancer Drug
Discovery, Volume (1). United Arab Emirates: Bentham Science Publishers.
39:
630:
366:
Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies. (2020). Singapore: Jenny Stanford Publishing.
251:
through advanced science and innovation, and also reflects our integrated development strategy in China and North America".
402:
391:
381:
371:
354:
344:
334:
324:
314:
304:
294:
284:
274:
234:
expressed by National Cancer Institute resulting in a drop of Entremed's stock price by $ 7.75 during November 1998.
485:
427:"HOPE IN THE LAB: A special report.; A Cautious Awe Greets Drugs That Eradicate Tumors in Mice (Published 1998)"
386:
Morris, S. A. (2018). Nanotheranostics for Cancer Applications. Germany: Springer International Publishing.
590:
376:
Jana, S. (2017). Particulate Technology for Delivery of Therapeutics. Singapore: Springer Singapore.
183:. In 2014 the company was renamed to CASI Pharmaceuticals to focus on products for the treatments of
279:
Rahman, A., Zaman, K. (2013). Topics in Anti-Cancer Research. (n.p.): Bentham Science Publishers.
175:
developing medicinal treatments for cancer. The company is primarily known for its producing the
172:
620:
238:
54:
763:"Long-standing Rockville biotechnology firm EntreMed changes name to CASI Pharmaceuticals"
715:
8:
204:
124:
531:
460:
796:"Rockville biopharma to sell first product on market in 28 years — but not in the U.S."
216:
150:
770:
743:
735:
689:
655:
626:
565:
434:
398:
387:
377:
367:
350:
340:
330:
320:
310:
300:
290:
280:
270:
727:
35:
616:
84:
819:
774:
739:
693:
659:
569:
438:
299:
Melanoma: Biologically Targeted Therapeutics. (2002). Ukraine: Humana Press.
132:
269:
The SAGE Handbook of Healthcare. (2008). United Kingdom: SAGE Publications.
747:
230:
176:
731:
682:"Company Is Stopping Its Work On a Prominent Cancer Drug (Published 1999)"
648:"A Failure to Verify A Cancer Advance Is Raising Concern (Published 1998)"
558:"A Failure to Verify A Cancer Advance Is Raising Concern (Published 1998)"
221:
225:
180:
44:
622:
When Science Offers Salvation: Patient Advocacy and Research Ethics
486:"QRxPharma Limited - Annual report for the year ended 30 June 2014"
192:
188:
128:
319:
Principles of Molecular Oncology. (2004). Ukraine: Humana Press.
184:
24:
195:. Wei-Wu He is the present chairman and CEO of the company.
154:
591:"A Case Study in How a Story Can Set Off a Frenzy"
817:
507:"Local biotech veteran John Holaday dies at 74"
720:JNCI: Journal of the National Cancer Institute
831:Pharmaceutical companies established in 1991
198:
713:
836:Health care companies based in Maryland
716:"Endostatin: Are We Waiting For Godot?"
615:
846:Companies based in Rockville, Maryland
826:American companies established in 1991
818:
760:
679:
424:
680:Morrow, David J. (10 February 1999).
645:
555:
420:
418:
18:
458:
237:Eventually EntreMed partnered with
13:
646:Grady, Denise (13 November 1998).
556:Grady, Denise (13 November 1998).
14:
857:
415:
714:Whitworth, Ariel (7 June 2006).
625:. Oxford University Press, USA.
23:
841:1991 establishments in Maryland
788:
761:Overly, Steven (16 June 2014).
754:
707:
673:
258:
16:US based pharmaceutical company
639:
609:
583:
549:
524:
499:
478:
452:
1:
408:
210:
360:
7:
425:Kolata, Gina (3 May 1998).
245:
203:EntreMed was co-founded in
96:; 33 years ago
10:
862:
263:
138:
120:
108:
90:
80:
199:History and description
38:, as no other articles
173:pharmaceutical company
167:, previously known as
532:"The cancer blockade"
239:Bristol-Myers Squibb
165:CASI Pharmaceuticals
799:www.bizjournals.com
732:10.1093/jnci/djj252
511:www.bizjournals.com
77:
686:The New York Times
652:The New York Times
597:. 13 February 2000
562:The New York Times
461:"Voodoo Investing"
459:Fumento, Michael.
431:The New York Times
217:The New York Times
75:
57:for suggestions.
47:to this page from
632:978-0-19-514313-3
619:(22 March 2001).
595:Los Angeles Times
493:QRxPharma Limited
162:
161:
112:Peter C. Farrell
71:
70:
853:
810:
809:
807:
805:
792:
786:
785:
783:
781:
758:
752:
751:
711:
705:
704:
702:
700:
677:
671:
670:
668:
666:
643:
637:
636:
617:Dresser, Rebecca
613:
607:
606:
604:
602:
587:
581:
580:
578:
576:
553:
547:
546:
544:
542:
528:
522:
521:
519:
517:
503:
497:
496:
490:
482:
476:
475:
473:
471:
456:
450:
449:
447:
445:
422:
158:
146:
104:
102:
97:
78:
74:
66:
63:
52:
50:related articles
27:
19:
861:
860:
856:
855:
854:
852:
851:
850:
816:
815:
814:
813:
803:
801:
794:
793:
789:
779:
777:
767:Washington Post
759:
755:
726:(11): 731–733.
712:
708:
698:
696:
678:
674:
664:
662:
644:
640:
633:
614:
610:
600:
598:
589:
588:
584:
574:
572:
554:
550:
540:
538:
530:
529:
525:
515:
513:
505:
504:
500:
488:
484:
483:
479:
469:
467:
457:
453:
443:
441:
423:
416:
411:
363:
266:
261:
248:
231:James D. Watson
213:
201:
148:
147:
144:
141:
115:
113:
100:
98:
95:
85:Pharmaceuticals
67:
61:
58:
48:
45:introduce links
28:
17:
12:
11:
5:
859:
849:
848:
843:
838:
833:
828:
812:
811:
787:
753:
706:
672:
638:
631:
608:
582:
548:
523:
498:
477:
451:
413:
412:
410:
407:
406:
405:
394:
384:
374:
362:
359:
358:
357:
347:
337:
327:
317:
307:
297:
287:
277:
265:
262:
260:
257:
247:
244:
212:
209:
200:
197:
171:is a US based
160:
159:
142:
139:
136:
135:
122:
118:
117:
110:
106:
105:
92:
88:
87:
82:
69:
68:
55:Find link tool
31:
29:
22:
15:
9:
6:
4:
3:
2:
858:
847:
844:
842:
839:
837:
834:
832:
829:
827:
824:
823:
821:
800:
797:
791:
776:
772:
768:
764:
757:
749:
745:
741:
737:
733:
729:
725:
721:
717:
710:
695:
691:
687:
683:
676:
661:
657:
653:
649:
642:
634:
628:
624:
623:
618:
612:
596:
592:
586:
571:
567:
563:
559:
552:
537:
533:
527:
512:
508:
502:
494:
487:
481:
466:
462:
455:
440:
436:
432:
428:
421:
419:
414:
404:
403:9781469874852
400:
395:
393:
392:9783030017750
389:
385:
383:
382:9789811036477
379:
375:
373:
372:9781000067378
369:
365:
364:
356:
355:9780801885266
352:
348:
346:
345:9781466851214
342:
338:
336:
335:9781593920333
332:
328:
326:
325:9781592596645
322:
318:
316:
315:9780137037094
312:
308:
306:
305:9781592591596
302:
298:
296:
295:9781608051618
292:
288:
286:
285:9781608051366
282:
278:
276:
275:9781847877000
272:
268:
267:
256:
252:
243:
240:
235:
232:
227:
223:
218:
215:In May 1998,
208:
206:
196:
194:
190:
186:
182:
178:
174:
170:
166:
156:
152:
143:
137:
134:
133:United States
130:
126:
123:
119:
114:Bart Chernow
111:
107:
93:
89:
86:
83:
79:
73:
65:
56:
51:
46:
42:
41:
37:
32:This article
30:
26:
21:
20:
802:. Retrieved
798:
790:
778:. Retrieved
766:
756:
723:
719:
709:
697:. Retrieved
685:
675:
663:. Retrieved
651:
641:
621:
611:
599:. Retrieved
594:
585:
573:. Retrieved
561:
551:
539:. Retrieved
535:
526:
514:. Retrieved
510:
501:
492:
480:
468:. Retrieved
464:
454:
442:. Retrieved
430:
259:Bibliography
253:
249:
236:
214:
202:
177:angiogenesis
168:
164:
163:
121:Headquarters
116:John Holaday
72:
59:
33:
804:22 November
780:22 November
699:22 November
665:22 November
601:22 November
575:22 November
541:22 November
516:22 November
470:22 November
444:22 November
222:angiostatin
820:Categories
409:References
226:endostatin
211:Endostatin
181:Endostatin
179:inhibitor
140:Key people
53:; try the
40:link to it
775:0190-8286
740:0027-8874
694:0362-4331
660:0362-4331
570:0362-4331
439:0362-4331
361:Footnotes
205:Rockville
145:Wei-Wu He
125:Rockville
43:. Please
748:16757695
246:Renaming
193:lymphoma
189:leukemia
169:EntreMed
151:Chairman
129:Maryland
109:Founders
81:Industry
76:EntreMed
62:May 2022
264:Sources
185:myeloma
99: (
91:Founded
773:
746:
738:
692:
658:
629:
568:
536:Forbes
465:Forbes
437:
401:
390:
380:
370:
353:
343:
333:
323:
313:
303:
293:
283:
273:
153:&
36:orphan
34:is an
489:(PDF)
806:2020
782:2020
771:ISSN
744:PMID
736:ISSN
701:2020
690:ISSN
667:2020
656:ISSN
627:ISBN
603:2020
577:2020
566:ISSN
543:2020
518:2020
472:2020
446:2020
435:ISSN
399:ISBN
388:ISBN
378:ISBN
368:ISBN
351:ISBN
341:ISBN
331:ISBN
321:ISBN
311:ISBN
301:ISBN
291:ISBN
281:ISBN
271:ISBN
224:and
101:1991
94:1991
728:doi
155:CEO
822::
769:.
765:.
742:.
734:.
724:98
722:.
718:.
688:.
684:.
654:.
650:.
593:.
564:.
560:.
534:.
509:.
491:.
463:.
433:.
429:.
417:^
191:,
187:,
131:,
127:,
808:.
784:.
750:.
730::
703:.
669:.
635:.
605:.
579:.
545:.
520:.
495:.
474:.
448:.
157:)
149:(
103:)
64:)
60:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
